MARKET

VIRI

VIRI

Virios Therapeutics Inc
NASDAQ
0.2516
-0.0115
-4.37%
After Hours: 0.2480 -0.0036 -1.43% 19:55 07/19 EDT
OPEN
0.2600
PREV CLOSE
0.2631
HIGH
0.2677
LOW
0.2201
VOLUME
1.63M
TURNOVER
0
52 WEEK HIGH
2.240
52 WEEK LOW
0.1557
MARKET CAP
6.98M
P/E (TTM)
-0.9409
1D
5D
1M
3M
1Y
5Y
1D
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Shares of Chuy’s Holdings, Inc. Rose sharply in today's pre-market trading. The company and Darden Restaurants announced that Darden will acquire Chuy's Holdings. Onconetix, Inc.'s shares rose 65% on Wednesday. Leslie's, Inc., and Stardust Power Inc. Were among the losers in pre- market trading.
Benzinga · 1d ago
Weekly Report: what happened at VIRI last week (0708-0712)?
Weekly Report · 4d ago
Weekly Report: what happened at VIRI last week (0701-0705)?
Weekly Report · 07/08 11:43
Weekly Report: what happened at VIRI last week (0624-0628)?
Weekly Report · 07/01 11:43
Weekly Report: what happened at VIRI last week (0617-0621)?
Weekly Report · 06/24 11:52
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading. The company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. SMX (Security Matters) shares jumped 109.8% on Tuesday.
Benzinga · 06/20 12:22
Virios Therapeutics Price Target Announced at $1.00/Share by Maxim Group
Dow Jones · 06/20 11:58
Virios Therapeutics Initiated at Buy by Maxim Group
Dow Jones · 06/20 11:58
More
About VIRI
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.

Webull offers Virios Therapeutics Inc stock information, including NASDAQ: VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.